한글목차

패혈증은 현대 의료에서 가장 긴급하고 비용이 많이 드는 과제 중 하나로 남아 있습니다. 감염에 대한 생명을 위협하는 면역 반응을 특징으로 하는 패혈증은 전 세계적으로 연간 약 2,700만 명에게 영향을 미치며 500만 명의 사망을 초래합니다. 이 중 미국에서만 약 200만건의 사례와 27만명의 사망이 보고되고 있습니다. 조기 발견은 생존율 향상에 극히 중요하지만, 환자마다 증상이 복잡하고 다양하여 여전히 어려운 상황입니다. 미국 병원에서 치료비가 가장 높은 질환으로서, 정확하고 신속하며 접근성이 좋은 진단 도구의 필요성은 그 어느 때보다 높아지고 있습니다.

Kalorama Information의 '세계의 패혈증 진단 제품 시장 동향 및 예측(-2031년)'은 체외 진단 의약품(IVD), 분자 진단, 관련 검사 기법을 포함한 패혈증 진단 제품의 세계 시장을 포괄적으로 평가합니다. 본 보고서는 주요 지역 전체 및 미국, 중국, 인도, 일본의 주요 개별 시장에 대해 2031년까지의

포괄적인 조사 방법론과 신뢰할 수 있는 데이터

시장 규모 추정치는 현재 미국 달러 기준으로 제시되며, 임상 검사실, 병원, 진료소의 패혈증 진단 제품 및 소모품에 대한 최종 사용자 총 지출액을 나타냅니다. 본 분석에서는 이러한 검사를 수행하는 진단 장비 및 시스템의 비용은 제외되어 보고된 수치가 제품 사용 동향을 정확히 반영하도록 보장됩니다. 모든 통화 환산은 지역 간 일관성을 유지하기 위해 구매력 평가지수를 사용하여 수행되었습니다.

본 조사는 업계 전문가 및 제조업체 인터뷰, 정부·업계 데이터, 시장 선도 기업의 최신 공개 자료 등 광범위한 1차 조사와 2차 조사에 기반합니다. 또한 Kalorama 선정 간행물 및 업계 보고서를 활용하여 조사 결과 검증과 새로운 동향 파악을 수행하고 있습니다.

본 보고서의 중요성

세계의 의료 시스템이 조기 발견, 비용 억제, 환자 결과를 우선시하는 가운데, 본 보고서는 패혈증 진단 시장 상황을 평가하는 데 필요한 핵심 시장 정보를 제공합니다. 데이터 기반의 토대로 다음과 같은 분석을 실현합니다.

• 주요 지역에 있어서 시장 규모의 추정과 예측
• 진단 개발 기업 간의 경쟁 벤치마킹
• 투자, 제휴, 제품 확대를 위한 전략적 계획 입안

패혈증의 임상적 및 경제적 부담이 혁신을 지속적으로 주도하는 가운데,“세계의 패혈증 진단 제품 시장 동향 및 예측(-2031년)” 은 의사 결정자가 성장하는 세계 의료 진단 분야에서 필수적인 인사이트을 얻고 방향을 설정하는 데 도움을 제공합니다.

목차

제1장 주요 요약

제2장 소개

• 패혈증의 개요
  • 진단 도구
  • 이용 범위
• 전문가용 가이드라인과 정의
  • SIRS 기준 및 패혈증-1
  • 패혈증-2
  • 패혈증-3
  • 패혈증 극복 캠페인
  • SOFA와 qSOFA 점수
• 시장 고려사항

제3장 바이오마커

• 젖산, C 반응성 단백질(CRP), 프로칼시토닌(PCT) 및 기타 바이오마커
• 개요
• 패혈증에 사용되는 바이오마커
  • 프로칼시토닌(PCT)
• C 반응성 단백질(CRP)
  • 젖산
  • 사이토카인
  • RNA, mRNA, 마이크로 RNA(miRNA)
  • 프로아드레노메듀린(ProADM)
  • D-다이머
• 멀티 마커 접근
  • 주요 기업과 플랫폼

제4장 분자 분석과 질량 분석

• 병원체 동정 및 특성 평가
• 멀티플렉스 분자 분석
  • 패혈증에 사용되는 멀티플렉스 분자 분석
  • 질량 분석
  • 미생물 식별 및 AST용 제품
  • 맞춤형 의료

제5장 시판 및 개발 중 주요 패혈증 관련 제품

• 진단제품과 신흥기술
• 제품 개발 문제
• 패혈증 진단에서 인공지능과 머신러닝

제6장 패혈증 진단 시장 예측

• 패혈증 진단 시장 전체
• 패혈증 바이오마커 시장
• 패혈증 분자 분석 및 질량 분석 시장
• 주요 기업의 경쟁상의 지위
• 마켓 리더의 논의

제7장 기업 프로파일

• 시장 역학
• ABBOTT
• ABIONIC
• ACCELERATE DIAGNOSTICS
• BAYESIAN HEALTH
• BECTON, DICKINSON AND COMPANY(BD)
• BIOMERIEUX
• BRUKER CORPORATION
• CELLECTRIC BIOSCIENCES
• CUBE DX
• CYTOVALE
• DANAHER CORPORATION
• DIASORIN
• FLUILUX
• GENMARK DIAGNOSTICS/HOLOGIC
• GRADIENTECH
• HELIXBIND
• IMMUNEXPRESS
• KARIUS
• INFLAMMATIX
• MEMED
• MOLZYM GMBH
• MOMENTUM BIOSCIENCES
• NOVUS DIAGNOSTICS
• OCEAN DX
• PRENOSIS
• Q-LINEA
• QIAGEN
• QUIDELORTHO
• RADIOMETER
• ROCHE
• SEEGENE
• SIEMENS HEALTHINEERS
• T2 BIOSYSTEMS
• TEMPUS
• THERMO FISHER SCIENTIFIC

영문목차

Sepsis remains one of the most urgent and costly challenges in modern healthcare. Characterized by a life-threatening immune response to infection, sepsis affects an estimated 27 million people and causes 5 million deaths worldwide each year, including approximately 2 million cases and 270,000 deaths in the United States alone. Early detection is critical to survival, yet remains difficult due to the condition's complex and variable presentation across patients. As the most expensive condition treated in U.S. hospitals, the need for accurate, rapid, and accessible diagnostic tools has never been greater.

Kalorama Information's "Worldwide Sepsis Diagnostic Products: Market Insights and Forecasts to 2031" delivers a comprehensive assessment of the worldwide market for sepsis diagnostic products, including in vitro diagnostics (IVD), molecular diagnostics, and related testing approaches. The report provides global sales data and projections through 2031 for all major world regions and for key individual markets-the United States, China, India, and Japan.

Comprehensive Methodology and Reliable Data

Market estimates are presented in current U.S. dollars, representing total end-user spending on sepsis diagnostic products and consumables by clinical laboratories, hospitals, and physicians' offices. The analysis excludes the cost of diagnostic instruments and systems implementing these tests, ensuring that reported figures specifically reflect product utilization trends. All currency conversions were made using purchasing power indices for consistency across regions.

The study is built upon extensive primary and secondary research, including interviews with industry experts and manufacturers, government and trade data, and the latest public filings from market leaders. Selected Kalorama publications and industry reports were also leveraged to validate findings and identify evolving trends.

Why This Report Matters

With healthcare systems worldwide prioritizing early detection, cost containment, and patient outcomes, this report provides the critical market intelligence needed to evaluate the sepsis diagnostics landscape. It offers a data-driven foundation for:

• Market sizing and forecasting across key geographies
• Competitive benchmarking among diagnostic developers
• Strategic planning for investment, partnerships, and product expansion

As the clinical and economic burden of sepsis continues to drive innovation, "Worldwide Sepsis Diagnostic Products: Market Insights and Forecasts to 2031" equips decision-makers with the insights necessary to navigate a growing and essential area of global healthcare diagnostics.

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

• OVERVIEW
• HIGHLIGHTS
  • Diagnostic Approaches and Technologies
  • Market Size and Competition
  • 3 Key Takeaways from This Report
• SCOPE AND METHODOLOGY
  • Methodology
  • Sources of Information
• ABOUT KALORAMA INFORMATION

CHAPTER 2: INTRODUCTION

• SEPSIS OVERVIEW
  • Diagnostic Tools
  • Scope of Use
• PROFESSIONAL GUIDELINES AND DEFINITIONS
  • SIRS Criteria and Sepsis-1
  • Sepsis-2
  • Sepsis-3
  • Surviving Sepsis Campaign
  • SOFA and qSOFA Scores
• MARKET CONSIDERATIONS
  • Table 2-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
  • Figure 2-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]

CHAPTER 3: BIOMARKERS

• Table 3-1: Top Biomarkers Used in Sepsis, 2025
• Lactate, C-Reactive Protein (CRP), Procalcitonin (PCT) and Other Biomarkers
• Overview
  • Figure 3-1: Global Market Share of Biomarkers Used in Sepsis Diagnosis, by Test Volume, 2025 (%) [C-Reactive Protein (CRP), Lactate, Procalcitonin (PCT) and Others]
  • Figure 3-2: Global Market Share of Biomarkers Used in Sepsis Diagnosis, by Sales Revenues, 2025 (%) [C-Reactive Protein (CRP), Lactate, Procalcitonin (PCT) and Others]
• BIOMARKERS USED FOR SEPSIS
  • Procalcitonin (PCT)
• C-Reactive Protein (CRP)
  • Lactate
  • Cytokines
  • RNA, mRNA, microRNA (miRNA)
  • Proadrenomedullin (ProADM)
  • D-Dimer
• MULTI-MARKER APPROACHES
  • Key Companies and Platforms

CHAPTER 4: MOLECULAR ASSAYS AND MASS SPECTROMETRY

• PATHOGEN IDENTIFICATION AND CHARACTERIZATION
• MULTIPLEX MOLECULAR ASSAYS
  • Multiplex Molecular Assays Used for Sepsis
    • Table 4-1: Multiplex Molecular Assays Used for Sepsis, 2025
  • Mass Spectrometry
  • Products for Microbe Identification and AST
    • Table 4-2: Selected Mass Spectrometry Products Used for Microbial ID and AST, 2025
    • Table 4-3: Systems and Products for Bacterial Culture, Staining, Incubation, 2025
  • Personalized Medicine

CHAPTER 5: MAJOR SEPSIS-RELATED PRODUCTS ON THE MARKET AND UNDER DEVELOPMENT

• DIAGNOSTIC PRODUCTS AND EMERGING TECHNOLOGIES
  • Table 5-1: Sepsis Diagnostic Products on the Market, 2025
• PRODUCT DEVELOPMENT ISSUES
  • The Challenge in Modern Sepsis Management
  • The Financial Incentive vs. The Adoption Hurdle
  • The Chasm Between Innovation and Practice
  • The Verification and Liability Problem
  • Current Status
• ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN SEPSIS DIAGNOSIS
  • Applications of AI/ML in Sepsis Diagnosis
  • Currently Available AI/ML Products for Sepsis Diagnosis
  • AI/ML Products Under Development and Emerging Trends
  • Future AI/ML Systems Are Integrating Diverse Data Types Beyond Standard EHRs
  • Challenges to Adoption and Performance
  • Future Trends

CHAPTER 6: SEPSIS DIAGNOSTICS MARKET ESTIMATES

• Total Sepsis Diagnostics Market
  • Table 6-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
  • Figure 6-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
  • Figure 6-2: Total Global Market Share for Sepsis Diagnostics, 2025 vs. 2031 (%) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
  • Table 6-2: Global Market for Sepsis Diagnostics, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Figure 6-3: Global Market for Sepsis Diagnostics, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Figure 6-4: Global Market for Sepsis Diagnostics, Share by Region, 2025 vs. 2031 (%) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
• Sepsis Biomarker Market
  • Table 6-3: Total Market for Sepsis Biomarkers, 2022-2031 ($ million) [Lab Immunoassay Tests, Rapid Immunoassay Tests]
  • Figure 6-5: Global Market for Sepsis Biomarkers, 2022-2031 ($ million) [Lab Immunoassay Tests, Rapid Immunoassay Tests]
  • Table 6-4: Global Market for Sepsis Biomarkers, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Figure 6-6: Global Market for Sepsis Biomarkers, Share by Region, 2025 vs. 2031 (%) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
• Market for Sepsis Molecular Assays and Mass Spectrometry
  • Table 6-5: Total Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, 2022-2031 ($ million)
  • Figure 6-7: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, 2022-2031 ($ million)
  • Table 6-6: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Figure 6-8: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Figure 6-9: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, by Region, 2025 vs. 2031 (%) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
• Competitive Positions of the Major Players
  • Table 6-7: Leading Providers of Sepsis Diagnostic Products, by 2025 Sales ($ million) and Share (%)
  • Figure 6-10: Leading Providers of Sepsis Diagnostic Products, by Sales, 2025 ($ million)
  • Figure 6-11: Leading Providers of Sepsis Diagnostic Products, by Share, 2025 (%)
• Market Leader Discussion

CHAPTER 7: COMPANY PROFILES

• MARKET DYNAMICS
  • Inactive Companies and Products
  • Companies No Longer Focused on Sepsis Diagnostics
  • Companies Currently Active in the Sepsis Diagnostics Market
• ABBOTT
  • Immunoassay Biomarkers
  • Molecular Diagnostics
  • Point-of-Care (POC) Solutions
  • Microbiology and Culture Systems
• ABIONIC
  • abioSCOPE-R Platform and PSP Test
  • Pancreatic Stone Protein (PSP) as a Sepsis Biomarker
  • Testing Process and Interpretation
  • Clinical Benefits of PSP Detection
  • Limitations and Future Outlook
• ACCELERATE DIAGNOSTICS
  • Core Technologies for Sepsis Management
  • Accelerate Pheno-R System
  • Accelerate Arc(TM) System
  • Future Innovation: Accelerate WAVE(TM) System
  • Strategic Impact on Sepsis Care
• BAYESIAN HEALTH
  • Sepsis Detection with TREWS
  • Workflow Integration and Explainability
  • Clinical Validation and Impact
  • Challenges and Future Outlook
  • Broader Applications
• BECTON, DICKINSON AND COMPANY (BD)
  • Blood Culture
  • Mass Spectrometry
• BIOMERIEUX
  • Traditional Microbiology
  • Biomarkers for Sepsis
  • Blood Culture Systems
  • Immunoassays
  • Mass Spectrometry
• BRUKER CORPORATION
  • Mass Spectrometry
  • Molecular Diagnostics
  • Strategic Acquisitions
• CELLECTRIC BIOSCIENCES
  • Benefits for Sepsis Diagnosis and Management
  • Limitations and Challenges
• CUBE DX
  • Core Technology and Applications
  • Technology Platform: hybcell
  • Benefits for Sepsis Management
  • Limitations and Considerations
• CYTOVALE
  • IntelliSep: Technology Overview
  • Risk Stratification Bands
  • Clinical Impact and Benefits
  • Limitations and Considerations
• DANAHER CORPORATION
  • Cepheid
  • Integrated Strategy
• DIASORIN
  • Molecular Diagnostics Expansion
• FLUILUX
  • Technology Overview
  • Clinical Impact on Sepsis Management
  • Limitations and Considerations
• GENMARK DIAGNOSTICS/HOLOGIC
• GRADIENTECH
• HELIXBIND
• IMMUNEXPRESS
  • SeptiCyte RAPID
  • Next Generation Products
• KARIUS
• INFLAMMATIX
  • TriVerity(TM)
  • Research
• MEMED
  • MeMed BV
  • MeMed Severity
• MOLZYM GMBH
  • MolYsis Technology
  • Diagnostic Products
  • Clinical Impact and Considerations
• MOMENTUM BIOSCIENCES
• NOVUS DIAGNOSTICS
• OCEAN DX
• PRENOSIS
• Q-LINEA
• QIAGEN
  • QIAstat-Dx
  • Sample Preparation Technologies
  • Digital PCR (dPCR)
  • Antimicrobial Resistance (AMR) Research Solutions
• QUIDELORTHO
  • VITROS Sepsis Assay Menu
  • Point-of-Care (POC) Testing Solutions
  • Benefits in Sepsis Management
  • Limitations and Considerations
• RADIOMETER
  • Blood Gas Analysis
  • Immunoassays
  • Integrated Solutions and Clinical Intelligence
• ROCHE
  • Biomarkers
  • Molecular Assays
  • Point-of-Care and Critical Care Solutions
  • Digital and Integrated Solutions
• SEEGENE
  • Magicplex(TM) Sepsis Real-time Test
  • Underlying Technology
  • Clinical Benefits
  • Limitations
• SIEMENS HEALTHINEERS
• T2 BIOSYSTEMS
  • The T2Dx-R Instrument
  • T2Candida-R Panel
  • T2Bacteria-R Panel
  • T2Resistance-R Panel
  • The T2MR Technology
• TEMPUS
• THERMO FISHER SCIENTIFIC
  • Immunoassays
  • Microbiology
  • Blood Culture